Results were presented in late May at the 10th Congress of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) held in Vancouver, BC, Canada.
Studies looking at benefits of supplementing with vegetarian, algae-derived DHA omega-3 fatty acids during pregnancy and infancy have shown positive results, according to results presented in late May at the 10th Congress of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) held in Vancouver, BC, Canada.
Prenatal algal DHA supplementation-that is, 600 mg DHA taken from 14 weeks gestation until delivery-increased DHA blood levels in both the mother and the newborn, as well as increased infant birth weight, length, and head circumference, said Susan E. Carlson, PhD, from the University of Kansas Medical Center’s Department of Dietetics and Nutrition.
Additionally, results from another study presented at the event had found that prenatal DHA deficiency may limit infants’ development potential. That study was led by Kelly Mulder, PhD, and Sheila Innis, PhD, both from the Department of Pediatrics, Child and Family Research Institute at the University of British Columbia.
Another study looked the benefits of algal DHA supplementation during infancy. Led by John Columbo, PhD, the DHA Intake and Measurement of Neural Development (DIAMOND) study indicated that supplementation with DHA and ARA omega fatty acids from 18 months to six years of age provided cognitive benefits and found that supplementation provided developmental benefits evident to six years of age.
DHA accounts for 97% of the omega-3 fats in the brain and up to 93% of the omega-3 fats in the retina.
The algae supplements used in these studies is DSM Nutritional Products’ life’sDHA brand of DHA omega-3 fatty acid.
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.